[go: up one dir, main page]

PL1839662T3 - Środek przeciwnowotworowy - Google Patents

Środek przeciwnowotworowy

Info

Publication number
PL1839662T3
PL1839662T3 PL06711726T PL06711726T PL1839662T3 PL 1839662 T3 PL1839662 T3 PL 1839662T3 PL 06711726 T PL06711726 T PL 06711726T PL 06711726 T PL06711726 T PL 06711726T PL 1839662 T3 PL1839662 T3 PL 1839662T3
Authority
PL
Poland
Prior art keywords
antitumor agent
antitumor
agent
Prior art date
Application number
PL06711726T
Other languages
English (en)
Inventor
Koji Yoshinaga
Daisuke Kawasaki
Yutaka Emori
Original Assignee
Zeria Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharm Co Ltd filed Critical Zeria Pharm Co Ltd
Publication of PL1839662T3 publication Critical patent/PL1839662T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06711726T 2005-01-19 2006-01-16 Środek przeciwnowotworowy PL1839662T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005011158 2005-01-19
PCT/JP2006/300445 WO2006077793A1 (ja) 2005-01-19 2006-01-16 抗腫瘍剤
EP06711726A EP1839662B1 (en) 2005-01-19 2006-01-16 Antitumor agent

Publications (1)

Publication Number Publication Date
PL1839662T3 true PL1839662T3 (pl) 2010-08-31

Family

ID=36692183

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06711726T PL1839662T3 (pl) 2005-01-19 2006-01-16 Środek przeciwnowotworowy

Country Status (17)

Country Link
US (5) US20080161293A1 (pl)
EP (1) EP1839662B1 (pl)
JP (1) JP4957250B2 (pl)
KR (1) KR101285047B1 (pl)
CN (1) CN101102776B (pl)
AU (1) AU2006207152B2 (pl)
BR (1) BRPI0606459A2 (pl)
CA (1) CA2594482C (pl)
DE (1) DE602006013094D1 (pl)
DK (1) DK1839662T3 (pl)
ES (1) ES2341728T3 (pl)
PL (1) PL1839662T3 (pl)
PT (1) PT1839662E (pl)
RU (1) RU2391982C2 (pl)
SI (1) SI1839662T1 (pl)
TW (1) TWI399206B (pl)
WO (1) WO2006077793A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006207152B2 (en) * 2005-01-19 2011-02-24 Zeria Pharmaceutical Co., Ltd. Antitumor agent
TWI459948B (zh) * 2008-05-15 2014-11-11 Zeria Pharm Co Ltd The use of a 1,5-benzodiazepine derivative or a pharmaceutically acceptable salt thereof for the manufacture of a pain therapeutic agent composition
JP5644110B2 (ja) 2008-08-05 2014-12-24 東レ株式会社 癌の検出方法
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
AU2010231439A1 (en) 2009-03-31 2011-10-27 Zeria Pharmaceutical Co., Ltd. Method for manufacturing 1,5-benzodiazepine derivative
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
US9772332B2 (en) 2012-07-19 2017-09-26 Toray Industries, Inc. Method for detecting CAPRIN-1 in a biological sample
JP6371063B2 (ja) * 2013-01-30 2018-08-08 国立大学法人 岡山大学 悪性腫瘍の検査方法および抗腫瘍剤
SI2979700T1 (sl) * 2013-03-27 2019-01-31 Taiho Pharmaceutical Co., Ltd. Protitumorsko sredstvo z nizko vsebnostjo irinotekan hidroklorid hidrata
CN105452294B (zh) 2013-08-09 2019-08-02 东丽株式会社 癌的治疗和/或预防用药物组合物
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
US10709714B2 (en) 2013-11-22 2020-07-14 Clifton Life Sciences LLC Gastrin antagonists for treatment and prevention of osteoporosis
CN108395410A (zh) * 2018-05-09 2018-08-14 日照市普达医药科技有限公司 一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用
CN114948927B (zh) * 2021-02-20 2024-10-15 无锡九基生物科技有限公司 一种含亚苄基的3-苯并呋喃酮衍生物在制备抗肿瘤药物中的应用
CN117263873A (zh) * 2022-06-15 2023-12-22 复旦大学 1,4-苯二氮䓬类化合物及其在制备抗肿瘤药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218115A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
IL104853A (en) * 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
JPH0840908A (ja) * 1994-07-28 1996-02-13 Yamanouchi Pharmaceut Co Ltd 癌細胞増殖抑制剤
EP0945445B9 (en) * 1996-12-10 2005-12-28 Zeria Pharmaceutical Co., Ltd. 1,5-benzodiazepine derivatives
JP2000026434A (ja) * 1998-06-05 2000-01-25 Zeria Pharmaceut Co Ltd 新規１，５−ベンゾジアゼピン誘導体
WO2000066125A1 (en) * 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6747022B2 (en) * 1999-12-02 2004-06-08 Zeria Pharmaceutical Co., Ltd. Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
CA2445477A1 (en) * 2001-05-11 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Antitumor agents
AU2006207152B2 (en) * 2005-01-19 2011-02-24 Zeria Pharmaceutical Co., Ltd. Antitumor agent

Also Published As

Publication number Publication date
DE602006013094D1 (de) 2010-05-06
US20170151256A1 (en) 2017-06-01
US20100143366A1 (en) 2010-06-10
TWI399206B (zh) 2013-06-21
SI1839662T1 (sl) 2010-07-30
HK1116064A1 (en) 2008-12-19
JPWO2006077793A1 (ja) 2008-06-19
AU2006207152A1 (en) 2006-07-27
US20080161293A1 (en) 2008-07-03
KR20070095930A (ko) 2007-10-01
BRPI0606459A2 (pt) 2009-06-30
CA2594482A1 (en) 2006-07-27
RU2007131435A (ru) 2009-02-27
US20100086553A1 (en) 2010-04-08
CA2594482C (en) 2013-10-01
CN101102776B (zh) 2011-08-24
DK1839662T3 (da) 2010-05-10
EP1839662B1 (en) 2010-03-24
EP1839662A1 (en) 2007-10-03
AU2006207152B2 (en) 2011-02-24
CN101102776A (zh) 2008-01-09
EP1839662A4 (en) 2008-05-21
WO2006077793A1 (ja) 2006-07-27
ES2341728T3 (es) 2010-06-25
US20180318314A1 (en) 2018-11-08
RU2391982C2 (ru) 2010-06-20
JP4957250B2 (ja) 2012-06-20
TW200637561A (en) 2006-11-01
KR101285047B1 (ko) 2013-07-10
PT1839662E (pt) 2010-04-28

Similar Documents

Publication Publication Date Title
PL2175273T3 (pl) Środek nadający kokumi
EP2062596A4 (en) ANTI-TUMOR AGENT
IL184788A0 (en) Quinoxaline derivatives as antitumor agents
DE502006001600D1 (en) Pyrazolylcarboxanilide
GB2440699B (en) Combination dolly-pallet
ZA200802813B (en) Antitumor agent
SI1839662T1 (sl) Antitumorsko sredstvo
EP1852112A4 (en) ANTITUMOR AGENTS
DE602006003064D1 (en) Tripeptid- und tetrapeptid-thioether
DE502005007477D1 (en) Delta-sigma-modulator
EP1719527A4 (en) ANTITUMORAL MEDIUM
EP1889660A4 (en) OZONE-GROWING AGENT
EP1927347A4 (en) MEANS TO REDUCE BITTERNESS
EP1852499A4 (en) AGENT PROMOTING NEUROTISATION
GB0523041D0 (en) Combination
GB0523040D0 (en) Combination
DE502006007734D1 (en) Thiazolcarbonsäureanilide
EP1867339A4 (en) ANTIVIRAL AGENT
GB0521981D0 (en) Weedsaway
GB0514758D0 (en) Anti-cancer agent
AU4036P (en) Dottie Calathea roseo-picta
AU3401P (en) Archise Arctotis fastuosa
AU3621P (en) Scacover Scaevola aemula
AU3393P (en) Breakwell xTriticosecale
AU3292P (en) DP303 Dianella prunina